New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful on the future of Type 2 diabetes care than advancements in diabetes medications.

美国2型糖尿病报告的新状态显示，大多数接受调查的医疗保健专业人员 (HCP) 认为，与糖尿病药物的进步相比，持续葡萄糖监测更有潜力对2型糖尿病护理的未来产生重大影响。

1

1

Dexcom Warrior Lance Bass will share first-hand experience saying “Bye” to fingersticks* during panel at ADA.

德克斯康战士兰斯·巴斯将在ADA小组会议上分享告别指尖采血*的亲身体验。

SAN DIEGO--(BUSINESS WIRE)--

圣地亚哥--(BUSINESS WIRE)--

DexCom, Inc., the global leader in glucose biosensing, today released its 'Dexcom State of Type 2 Report: Access and Attitudes Across the United States' ahead of the 85

德康公司（DexCom, Inc.），作为全球葡萄糖生物传感领域的领导者，今天发布了其《德康2型糖尿病报告：美国各地的获取途径与态度》。

th

th

Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States.

美国糖尿病协会（ADA）在芝加哥举行的科学会议。这些发现为美国各地400多名医疗保健专业人员和2型糖尿病患者对糖尿病技术的看法提供了宝贵的见解。

New State of Type 2 Report in the United States reports that a majority of HCPs surveyed believe continuous glucose monitoring will have the potential to be more impactful on the future of Type 2 diabetes care than advancements in diabetes medications.

美国的《2型糖尿病报告》新状态指出，大多数受访的医疗保健专业人士认为，与糖尿病药物的进步相比，持续血糖监测有望对2型糖尿病护理的未来产生更大的影响。

During the conference, Dexcom will present extensive clinical data that shows the benefits of CGM for those living with Type 2 diabetes as well as new outcomes from early Stelo users.

在会议期间，Dexcom将展示大量的临床数据，显示CGM对2型糖尿病患者以及早期Stelo用户的新成果带来的益处。

Dexcom releases new State of Type 2 Report: Access and Attitudes Across the United States

德康发布新的2型糖尿病报告：美国各地的获取途径与态度

Earlier this year, Dexcom announced the release of its first multi-region report, detailing access and attitudes of individuals diagnosed with Type 2 diabetes and healthcare professionals across Europe and the Middle East (EMEA). The latest State of Type 2 Report now builds on those initial findings with data collected in the U.S.

今年早些时候，Dexcom 宣布发布其首份多地区报告，详细介绍了欧洲和中东 (EMEA) 地区被诊断为 2 型糖尿病的患者及医疗专业人士的使用情况与态度。最新的《2 型糖尿病现状报告》现在基于美国收集的数据，进一步深化了这些初步发现。

Topline takeaways include:.

头条要点包括：。

Tech is believed to be an effective way to manage Type 2 diabetes:

技术被认为是一种管理2型糖尿病的有效方法：

More than half (59%) of U.S. HCPs believe that better access to CGM will be the most effective way to help people with Type 2 diabetes manage their condition over the next decade.

超过一半（59%）的美国医疗保健专业人员认为，在未来十年内，更好的动态血糖监测（CGM）获取途径将是帮助2型糖尿病患者管理病情的最有效方法。

1

1

U.S. HCPs support CGM as “standard of care”:

美国医疗保健专业人士支持将CGM作为“护理标准”：

96% of providers surveyed in the U.S. agree that CGM should be the standard of care for individuals using multiple daily insulin injections, and 94% agree that CGM should be the standard of care for those on basal insulin.

接受调查的美国医生中，96% 认为 CGM 应该是每天多次注射胰岛素的患者的标准护理方式，94% 认为 CGM 应该是使用基础胰岛素的患者的标准护理方式。

1

1

U.S. HCPs unanimously support use of CGM in combination with GLP-1 medications:

美国医疗保健专业人士一致支持将CGM与GLP-1药物联合使用：

100% of U.S. HCPs surveyed recommend CGM in combination with GLP-1 or SGLT2 medication because it has the best expected outcomes for patients, and 79% of providers in EMEA agreed.

接受调查的100%的美国医疗保健专业人员推荐将CGM与GLP-1或SGLT2药物联合使用，因为它对患者有最佳的预期效果，而79%的欧洲、中东和非洲地区的医疗服务提供者表示同意。

1

1

Better coverage, more education and training can improve understanding of CGM:

更好的覆盖范围、更多的教育和培训可以提高对CGM的理解：

HCPs believe access and understanding about the usage of CGM can be improved with additional coverage and more educational support for Americans with Type 2 diabetes, as well as more training for healthcare providers. Specifically, 60% of U.S. HCPs said additional funding or budget to cover CGM could increase usage among people with Type 2 diabetes.

医疗保健从业者（HCPs）认为，通过扩大覆盖范围、为美国2型糖尿病患者提供更多教育支持以及加强对医疗服务提供者的培训，可以改善对连续血糖监测（CGM）使用的获取和理解。具体而言，60%的美国医疗保健从业者表示，增加用于覆盖CGM的额外资金或预算可能会提高2型糖尿病患者的使用率。

.

。

1

1

“The findings of our State of Type 2 Report in the U.S. reaffirm what we’ve always believed to be true: CGM is central to the future of Type 2 diabetes care,” said Jake Leach, president and chief operating officer of Dexcom. “To help drive the greatest impact for patients, a continued focus on diabetes education and access to CGMs is needed – and Dexcom is committed to advancing these around the world.”.

“我们在美国的《2型糖尿病状况报告》的调查结果再次证实了我们一直以来的信念：连续血糖监测（CGM）是2型糖尿病护理未来的核心，”德康公司总裁兼首席运营官杰克·里奇表示。“为了对患者产生最大的影响，我们需要持续关注糖尿病教育和CGM的可及性——德康致力于在全球范围内推动这些方面的发展。”

Read the full Dexcom State of Type 2 Report here:

在此处阅读完整的 Dexcom 2型糖尿病报告：

https://provider.dexcom.com/future-type-2-diabetes-care

https://provider.dexcom.com/future-type-2-diabetes-care

Dexcom presents robust clinical data and hosts compelling presentations

德康展示了强有力的临床数据并举办了引人入胜的演讲

Conference attendees will have the opportunity to hear firsthand from Grammy-nominated singer, actor, producer and Dexcom Warrior Lance Bass about how Dexcom CGM has helped him live his best life during Dexcom’s product theater on Saturday, June 21.

与会者将有机会在6月21日（星期六）举行的Dexcom产品剧院活动中，亲耳聆听格莱美提名歌手、演员、制片人以及Dexcom战士Lance Bass讲述Dexcom CGM如何帮助他过上最佳生活。

After being diagnosed with Latent Autoimmune Diabetes in Adults (LADA), also known as Type 1.5 diabetes, Lance has been an advocate for the diabetes community, saying ‘Bye’ to fingersticks*, guesswork and uncertainty with the help of Dexcom G7 technology. Lance will be joined by experts who will also speak about how early adoption of CGM can improve diabetes management through personalized care in addition to innovations in Dexcom technology, including new features and in-app reports..

在被诊断出患有成人隐匿性自身免疫糖尿病 (LADA)，也称为1.5型糖尿病后，兰斯一直致力于为糖尿病患者群体发声。借助Dexcom G7技术，他说“再见”于指尖采血、猜测和不确定性。兰斯将与多位专家共同出席，这些专家还将讨论早期采用CGM（连续血糖监测）如何通过个性化护理改善糖尿病管理，此外还会介绍Dexcom技术的创新，包括新功能和应用内报告。

Additionally, Dexcom will present clinical data at the conference that continues to support the benefits of its technology for people with diabetes of all ages and stages. Most notably, several studies looking at CGM use for those with Type 2 diabetes across various insulin therapies show numerous benefits – adding to an already extensive body of evidence – from reduced mortality risk among insulin-using people.

此外，德康公司还将在会议上展示继续支持其技术对所有年龄和阶段的糖尿病患者有益的临床数据。最值得注意的是，有几项研究针对使用各种胰岛素疗法的2型糖尿病患者使用CGM的情况，显示出诸多益处——这为已经相当丰富的证据又增添了新的支持——其中包括降低使用胰岛素患者的死亡风险。

2

2

to reduced diabetes-related distress and improved self-management

减少糖尿病相关的困扰并改善自我管理

3

3

among non-insulin using people.

在非胰岛素使用人群中。

In a real-world observational study of individuals with Type 2 diabetes not using insulin, Dexcom G7 use was associated with significantly reduced diabetes-related distress and increased adherence to healthy eating plans and exercise routines, supporting CGM as a powerful tool for behavior modification..

在一项针对未使用胰岛素的 2 型糖尿病患者的真实世界观察性研究中，使用 Dexcom G7 与显著降低的糖尿病相关痛苦以及对健康饮食计划和锻炼习惯的依从性增加相关，这支持了 CGM 作为行为改变的强大工具。

3

3

For a detailed overview of all Dexcom presentations at ADA this year, visit:

要详细了解今年ADA上所有Dexcom的展示内容，请访问：

https://professional.diabetes.org/scientific-sessions

https://professional.diabetes.org/scientific-sessions

.

。

About DexCom, Inc.

关于DexCom公司。

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently..

Dexcom通过创新的生物传感技术，帮助人们掌控健康。自1999年成立以来，Dexcom在葡萄糖生物传感领域开创先河，并制定了超过25年的行业标准。其技术已经改变了人们管理糖尿病和监测血糖的方式，帮助他们获得更多掌控感，并更加自信地生活。

Dexcom. Discover what you’re made of. For more information, visit

德康。发现你的内在力量。欲了解更多信息，请访问

www.dexcom.com

www.dexcom.com

.

。

Category: IR

类别：IR

____________________

____________________

*

*

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

如果症状或预期与读数不符，糖尿病治疗决策需要进行指尖采血。

1 Dexcom State of Type 2 Report (US), Dexcom data on file, 2025.

1 Dexcom 2型糖尿病报告（美国），Dexcom数据存档，2025年。

2

2

Blake CL, et al. “Reduced Mortality Risk Associated with Dexcom rtCGM Compared to SMBG Among People with T2D on Any Insulin Therapy.” Presented at ADA 2025. 3

Blake CL 等人。“在使用任意胰岛素治疗的2型糖尿病患者中，与SMBG相比，使用德康rtCGM可降低死亡风险。” 在ADA 2025上发表。3

Crawford, MA, et al. “Real-World Dexcom CGM Use in T2D NIT: Reduced Diabetes Distress and Improved Self-Care Behaviors.” Presented at ADA 2025.

克劳福德，MA，等。《2型糖尿病非胰岛素治疗中实际使用德康CGM：减轻糖尿病困扰并改善自我护理行为》。ADA 2025年会上发表。

Media Relations Contact

媒体关系联系人

Nadia Conard

纳迪亚·康拉德

mediarelations@dexcom.com

媒体关系@德康公司. com

Investor Relations Contact

投资者关系联系人

Sean Christensen

肖恩·克里斯滕森

sean.christensen@dexcom.com

肖恩·克里斯滕森@德克斯康姆.康姆

Source: DexCom, Inc.

来源：DexCom公司